The trinity of the cortical actin in the initiation of HIV-1 infection

Retrovirology

Yuntao Wu¹  Jia Guo¹  Mark Spear¹ 

[1] National Center for Biodefense and Infectious Diseases, Department of Molecular and Microbiology, George Mason University, Manassas, VA, 20110, USA

关键词: Chemotaxis;    Chemokine;    CXCR4;    CD4;    Arp2/3;    LIMK1;    Cofilin;    Actin;    Nef;    gp120;    HIV-1;   

Others  :  1209298
DOI  :  10.1186/1742-4690-9-45

 received in 2012-03-02, accepted in 2012-05-03,  发布年份 2012

【 摘 要 】

For an infecting viral pathogen, the actin cortex inside the host cell is the first line of intracellular components that it encounters. Viruses devise various strategies to actively engage or circumvent the actin structure. In this regard, the human immunodeficiency virus-1 (HIV-1) exemplifies command of cellular processes to take control of actin dynamics for the initiation of infection. It has becomes increasingly evident that cortical actin presents itself both as a barrier to viral intracellular migration and as a necessary cofactor that the virus must actively engage, particularly, in the infection of resting CD4 blood T cells, the primary targets of HIV-1. The coercion of this most fundamental cellular component permits infection by facilitating entry, reverse transcription, and nuclear migration, three essential processes for the establishment of viral infection and latency in blood T cells. It is the purpose of this review to examine, in detail, the manifestation of viral dependence on the actin cytoskeleton, and present a model of how HIV utilizes actin dynamics to initiate infection.

【 授权许可】

   
2012 Spear et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pollard TD, Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112:453-465.
• [2]Loisel TP, Boujemaa R, Pantaloni D, Carlier MF: Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature 1999, 401:613-616.
• [3]Cameron LA, Giardini PA, Soo FS, Theriot JA: Secrets of actin-based motility revealed by a bacterial pathogen. Nat Rev Mol Cell Biol 2000, 1:110-119.
• [4]Frischknecht F, Moreau V, Rottger S, Gonfloni S, Reckmann I, Superti-Furga G, Way M: Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature 1999, 401:926-929.
• [5]Goley ED, Ohkawa T, Mancuso J, Woodruff JB, D'Alessio JA, Cande WZ, Volkman LE, Welch MD: Dynamic nuclear actin assembly by Arp2/3 complex and a baculovirus WASP-like protein. Science 2006, 314:464-467.
• [6]Ohkawa T, Volkman LE, Welch MD: Actin-based motility drives baculovirus transit to the nucleus and cell surface. Journal of Cell Biology 2010, 190:187-195.
• [7]Hottiger M, Gramatikoff K, Georgiev O, Chaponnier C, Schaffner W, Hubscher U: The large subunit of HIV-1 reverse transcriptase interacts with beta-actin. Nucleic Acids Res 1995, 23:736-741.
• [8]Rey O, Canon J, Krogstad P: HIV-1 Gag protein associates with F-actin present in microfilaments. Virology 1996, 220:530-534.
• [9]Ibarrondo FJ, Choi R, Geng YZ, Canon J, Rey O, Baldwin GC, Krogstad P: HIV type 1 Gag and nucleocapsid proteins: cytoskeletal localization and effects on cell motility. AIDS Res Hum Retroviruses 2001, 17:1489-1500.
• [10]Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF: Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol 1999, 73:2901-2908.
• [11]Wilk T, Gowen B, Fuller SD: Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. J Virol 1999, 73:1931-1940.
• [12]Fackler OT, Kienzle N, Kremmer E, Boese A, Schramm B, Klimkait T, Kucherer C, Mueller-Lantzsch N: Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization. Eur J Biochem 1997, 247:843-851.
• [13]Turlure F, Devroe E, Silver PA, Engelman A: Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci 2004, 9:3187-3208.
• [14]Niederman TM, Hastings WR, Ratner L: Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology 1993, 197:420-425.
• [15]Aiken C: Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71:5871-5877.
• [16]Chazal N, Singer G, Aiken C, Hammarskjold ML, Rekosh D: Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 2001, 75:4014-4018.
• [17]Luo T, Douglas JL, Livingston RL, Garcia JV: Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 1998, 241:224-233.
• [18]Campbell EM, Nunez R, Hope TJ: Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. Journal of Virology 2004, 78:5745-5755.
• [19]Yu D, Wang W, Yoder A, Spear M, Wu Y: The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog 2009, 5:e1000633.
• [20]Agosto LM, Yu JJ, Liszewski MK, Baytop C, Korokhov N, Humeau LM, O'Doherty U: The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol 2009, 83:8153-8162.
• [21]Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB: HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
• [22]Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG: pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49:659-668.
• [23]Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, Axel R: HIV infection does not require endocytosis of its receptor, CD4. Cell 1988, 54:865-874.
• [24]McClure MO, Marsh M, Weiss RA: Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. Embo J 1988, 7:513-518.
• [25]Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR: Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 2002, 277:17291-17299.
• [26]Pelchen-Matthews A, Clapham P, Marsh M: Role of CD4 endocytosis in human immunodeficiency virus infection. J Virol 1995, 69:8164-8168.
• [27]Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, et al.: HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 2008, 134:782-792.
• [28]Vorster PJ, Guo J, Yoder A, Wang W, Zheng Y, Xu X, Yu D, Spear M, Wu Y: LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection. J Biol Chem 2011, 286:12554-12564.
• [29]Guo J, Wang W, Yu D, Wu Y: Spinoculation triggers dynamic actin and cofilin activity facilitating HIV-1 infection of transformed and resting CD4 T cells. J Virol 2011, 85:9824-9833.
• [30]Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, Boucher G, Haddad EK, Sekaly RP, Harman AN, et al.: Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 2010, 107:16934-16939.
• [31]Wu Y, Yoder A: Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 2009, 5:e1000520.
• [32]Wu Y: The co-receptor signaling model of HIV-1 pathogenesis in peripheral CD4 T cells. Retrovirology 2009, 6:41. BioMed Central Full Text
• [33]Wu Y: Chemokine control of HIV-1 infection: beyond a binding competition. Retrovirology 2010, 7:86. BioMed Central Full Text
• [34]Bukrinsky M: How to engage Cofilin. Retrovirology 2008, 5:85. BioMed Central Full Text
• [35]Liu Y, Belkina NV, Shaw S: HIV infection of T cells: actin-in and actin-out. Sci Signal 2009, 2:pe23.
• [36]Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC, et al.: Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984, 225:59-63.
• [37]Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
• [38]Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
• [39]McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, Hicks D, Sligh J: Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol 1985, 135:3151-3162.
• [40]McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK: Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110 K viral protein and the T4 molecule. Science 1986, 231:382-385.
• [41]Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
• [42]Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
• [43]Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
• [44]Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
• [45]Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
• [46]Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
• [47]Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
• [48]Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
• [49]Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H: Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996, 274:602-605.
• [50]Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183.
• [51]Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
• [52]Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997, 71:6296-6304.
• [53]Ugolini S, Moulard M, Mondor I, Barois N, Demandolx D, Hoxie J, Brelot A, Alizon M, Davoust J, Sattentau QJ: HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. J Immunol 1997, 159:3000-3008.
• [54]Iyengar S, Hildreth JE, Schwartz DH: Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J Virol 1998, 72:5251-5255.
• [55]Jimenez-Baranda S, Gomez-Mouton C, Rojas A, Martinez-Prats L, Mira E, Ana Lacalle R, Valencia A, Dimitrov DS, Viola A, Delgado R, et al.: Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol 2007, 9:838-846.
• [56]Barrero-Villar M, Cabrero JR, Gordon-Alonso M, Barroso-Gonzalez J, Alvarez-Losada S, Munoz-Fernandez MA, Sanchez-Madrid F, Valenzuela-Fernandez A: Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes. J Cell Sci 2009, 122:103-113.
• [57]Pontow SE, Heyden NV, Wei S, Ratner L: Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. Journal of Virology 2004, 78:7138-7147.
• [58]Harmon B, Ratner L: Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J Virol 2008, 82:9191-9205.
• [59]Harmon B, Campbell N, Ratner L: Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog 2010, 6:e1000956.
• [60]Lapham CK, Zaitseva MB, Lee S, Romanstseva T, Golding H: Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat Med 1999, 5:303-308.
• [61]Xiao X, Wu L, Stantchev TS, Feng YR, Ugolini S, Chen H, Shen Z, Riley JL, Broder CC, Sattentau QJ, Dimitrov DS: Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci U S A 1999, 96:7496-7501.
• [62]Singer II, Scott S, Kawka DW, Chin J, Daugherty BL, DeMartino JA, DiSalvo J, Gould SL, Lineberger JE, Malkowitz L, et al.: CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol 2001, 75:3779-3790.
• [63]Baker AM, Sauliere A, Gaibelet G, Lagane B, Mazeres S, Fourage M, Bachelerie F, Salome L, Lopez A, Dumas F: CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach. J Biol Chem 2007, 282:35163-35168.
• [64]Toth PT, Ren D, Miller RJ: Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study. J Pharmacol Exp Ther 2004, 310:8-17.
• [65]Seror C, Melki MT, Subra F, Raza SQ, Bras M, Saidi H, Nardacci R, Voisin L, Paoletti A, Law F, et al.: Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med 2011, 208:1823-1834.
• [66]Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864.
• [67]Layne SP, Merges MJ, Dembo M, Spouge JL, Nara PL: HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 1990, 346:277-279.
• [68]Kuhmann SE, Platt EJ, Kozak SL, Kabat D: Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000, 74:7005-7015.
• [69]Sougrat R, Bartesaghi A, Lifson JD, Bennett AE, Bess JW, Zabransky DJ, Subramaniam S: Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 2007, 3:e63.
• [70]Del Real G, Jimenez-Baranda S, Lacalle RA, Mira E, Lucas P, Gomez-Mouton C, Carrera AC, Martinez AC, Manes S: Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002, 196:293-301.
• [71]Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, Sanchez-Palomino S, Delgado R, Alcami J, Mira E, Martinez AC: Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000, 1:190-196.
• [72]Popik W, Alce TM, Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002, 76:4709-4722.
• [73]Kamiyama H, Yoshii H, Tanaka Y, Sato H, Yamamoto N, Kubo Y: Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Virology 2009, 386:23-31.
• [74]Nguyen DH, Giri B, Collins G, Taub DD: Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp Cell Res 2005, 304:559-569.
• [75]Popik W, Alce TM: CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4. J Biol Chem 2004, 279:704-712.
• [76]Percherancier Y, Lagane B, Planchenault T, Staropoli I, Altmeyer R, Virelizier JL, Arenzana-Seisdedos F, Hoessli DC, Bachelerie F: HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J Biol Chem 2003, 278:3153-3161.
• [77]Balabanian K, Harriague J, Decrion C, Lagane B, Shorte S, Baleux F, Virelizier JL, Arenzana-Seisdedos F, Chakrabarti LA: CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J Immunol 2004, 173:7150-7160.
• [78]Chang MI, Panorchan P, Dobrowsky TM, Tseng Y, Wirtz D: Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells. J Virol 2005, 79:14748-14755.
• [79]Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, Blumenthal R: Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology 2006, 3:90. BioMed Central Full Text
• [80]Gallo SA, Puri A, Blumenthal R: HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 2001, 40:12231-12236.
• [81]Readinger JA, Schiralli GM, Jiang JK, Thomas CJ, August A, Henderson AJ, Schwartzberg PL: Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci U S A 2008, 105:6684-6689.
• [82]Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, Venkatesan S, Farber JM, Fauci AS: Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 1997, 389:981-985.
• [83]Komano J, Miyauchi K, Matsuda Z, Yamamoto N: Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Mol Biol Cell 2004, 15:5197-5207.
• [84]Naghavi MH, Valente S, Hatziioannou T, de Los Santos K, Wen Y, Mott C, Gundersen GG, Goff SP: Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells. Embo J 2007, 26:41-52.
• [85]Arthur LO, Bess JW, Sowder RC, Benveniste RE, Mann DL, Chermann JC, Henderson LE: Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992, 258:1935-1938.
• [86]Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC, Kim YD, Fisher RJ, Zhou XZ, Lu KP, Henderson LE: Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology 2000, 266:42-51.
• [87]Ott DE, Coren LV, Kane BP, Busch LK, Johnson DG, Sowder RC, Chertova EN, Arthur LO, Henderson LE: Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 1996, 70:7734-7743.
• [88]Junghans RP, Duesberg PH, Knight CA: In vitro synthesis of full-length DNA transcripts of Rous sarcoma virus RNA by viral DNA polymerase. Proc Natl Acad Sci U S A 1975, 72:4895-4899.
• [89]Zhang H, Zhang Y, Spicer TP, Abbott LZ, Abbott M, Poiesz BJ: Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Res Hum Retroviruses 1993, 9:1287-1296.
• [90]Lori F, di Marzo Veronese F, de Vico AL, Lusso P, Reitz MS, Gallo RC: Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992, 66:5067-5074.
• [91]Trono D: Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992, 66:4893-4900.
• [92]Warrilow D, Stenzel D, Harrich D: Isolated HIV-1 core is active for reverse transcription. Retrovirology 2007, 4:77. BioMed Central Full Text
• [93]Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
• [94]Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M: Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A 1996, 93:15266-15271.
• [95]Varmus HE, Padgett T, Heasley S, Simon G, Bishop JM: Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. Cell 1977, 11:307-319.
• [96]Zhang H, Bagasra O, Niikura M, Poiesz BJ, Pomerantz RJ: Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol 1994, 68:7591-7597.
• [97]Zhang H, Zhang Y, Spicer T, Henrard D, Poiesz BJ: Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. J Virol 1995, 69:3675-3682.
• [98]Zhang H, Dornadula G, Orenstein J, Pomerantz RJ: Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. J Hum Virol 2000, 3:165-172.
• [99]Forshey BM, von Schwedler U, Sundquist WI, Aiken C: Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002, 76:5667-5677.
• [100]Dismuke DJ, Aiken C: Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol 2006, 80:3712-3720.
• [101]Warrilow D, Harrich D: HIV-1 replication from after cell entry to the nuclear periphery. Curr HIV Res 2007, 5:293-299.
• [102]Merrifield CJ, Perrais D, Zenisek D: Coupling between clathrin-coated-pit invagination, cortactin recruitment, and membrane scission observed in live cells. Cell 2005, 121:593-606.
• [103]Brun S, Solignat M, Gay B, Bernard E, Chaloin L, Fenard D, Devaux C, Chazal N, Briant L: VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology 2008, 5:57. BioMed Central Full Text
• [104]Arhel N: Revisiting HIV-1 uncoating. Retrovirology 2011, 7:96.
• [105]Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S, Puthavathana P: Uncoating of HIV-1 requires cellular activation. Virology 2005, 337:93-101.
• [106]Marcy Y, Prost J, Carlier MF, Sykes C: Forces generated during actin-based propulsion: a direct measurement by micromanipulation. Proc Natl Acad Sci U S A 2004, 101:5992-5997.
• [107]Abraham VC, Krishnamurthi V, Taylor DL, Lanni F: The actin-based nanomachine at the leading edge of migrating cells. Biophys J 1999, 77:1721-1732.
• [108]Bukrinskaya A, Brichacek B, Mann A, Stevenson M: Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998, 188:2113-2125.
• [109]Wu Y, Beddall MH, Marsh JW: Rev-dependent lentiviral expression vector. Retrovirology 2007, 4:12. BioMed Central Full Text
• [110]Wu Y, Beddall MH, Marsh JW: Rev-dependent indicator T cell line. Current HIV Research 2007, 5:395-403.
• [111]Kestler HWd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
• [112]Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC: Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 1994, 68:2906-2914.
• [113]Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB: The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994, 179:101-113.
• [114]Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69:5048-5056.
• [115]Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC: The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 1995, 212:451-457.
• [116]Schwartz O, Marechal V, Danos O, Heard JM: Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995, 69:4053-4059.
• [117]Kotov A, Zhou J, Flicker P, Aiken C: Association of Nef with the human immunodeficiency virus type 1 core. J Virol 1999, 73:8824-8830.
• [118]Forshey BM, Aiken C: Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol 2003, 77:4409-4414.
• [119]Zhou Y, Zhang H, Siliciano JD, Siliciano RF: Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 2005, 79:2199-2210.
• [120]Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61:213-222.
• [121]Korin YD, Zack JA: Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 1999, 73:6526-6532.
• [122]Campbell GR, Spector SA: CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem 2008, 283:30745-30753.
• [123]Miller MD, Farnet CM, Bushman FD: Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997, 71:5382-5390.
• [124]McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ: Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002, 159:441-452.
• [125]Arhel N, Genovesio A, Kim KA, Miko S, Perret E, Olivo-Marin JC, Shorte S, Charneau P: Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods 2006, 3:817-824.
• [126]Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992, 66:2232-2239.
• [127]Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV: Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002, 76:11440-11446.
• [128]Wei BL, Denton PW, O'Neill E, Luo T, Foster JL, Garcia JV: Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol 2005, 79:5705-5712.
• [129]Zamborlini A, Lehmann-Che J, Clave E, Giron ML, Tobaly-Tapiero J, Roingeard P, Emiliani S, Toubert A, de The H, Saib A: Centrosomal pre-integration latency of HIV-1 in quiescent cells. Retrovirology 2007, 4:63. BioMed Central Full Text
• [130]Suzuki Y, Craigie R: The road to chromatin - nuclear entry of retroviruses. Nat Rev Microbiol 2007, 5:187-196.
• [131]Yoder A, Guo J, Yu D, Cui Z, Zhang XE, Wu Y: Effects of Microtubule Modulators on HIV-1 Infection of Transformed and Resting CD4 T Cells. J Virol 2011, 85:3020-3024.
• [132]Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR: CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007, 110:4161-4164.
• [133]Cameron PU, Saleh SM, Sallman G, Solomon A, Wightman F, Mark J, Hones K, Anderson J, Jaworowski A, Lewin SR: Latent HIV infection can be established in resting CD4+ T-cells in vitro following incubation with multiple diverse chemokines which facilitate nuclear import of the pre-integration complex. 4th international workship in HIV persistence during therapy 2009, 2009:8-11.
• [134]Gey GO, Bang FB, Gey MK: Responses of a variety of normal and malignant cells to continuous cultivation, and some practical applications of these responses to problems in the biology of disease. Ann N Y Acad Sci 1954, 58:976-999.
• [135]Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA: High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1995, 92:7739-7743.
• [136]Forestell SP, Dando JS, Bohnlein E, Rigg RJ: Improved detection of replication-competent retrovirus. J Virol Methods 1996, 60:171-178.
• [137]Ho WZ, Cherukuri R, Ge SD, Cutilli JR, Song L, Whitko S, Douglas SD: Centrifugal enhancement of human immunodeficiency virus type 1 infection and human cytomegalovirus gene expression in human primary monocyte/macrophages in vitro. J Leukoc Biol 1993, 53:208-212.
• [138]O'Doherty U, Swiggard WJ, Malim MH: Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000, 74:10074-10080.
• [139]Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996, 2:1244-1247.
• [140]Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, Gerard NP, Sodroski J, Gerard C: HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. Journal of Biological Chemistry 1997, 272:6854-6857.
• [141]Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA: HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997, 234:340-348.
• [142]Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, Goldsmith MA, Charo IF: Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A 1997, 94:5061-5066.
• [143]Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG: Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. Embo J 1997, 16:4606-4616.
• [144]Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, Baggiolini M, Virelizier JL, Arenzana-Seisdedos F: HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997, 186:139-146.
• [145]Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, et al.: Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A 1997, 94:6426-6431.
• [146]Doranz BJ, Orsini MJ, Turner JD, Hoffman TL, Berson JF, Hoxie JA, Peiper SC, Brass LF, Doms RW: Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol 1999, 73:2752-2761.
• [147]Brelot A, Heveker N, Montes M, Alizon M: Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 2000, 275:23736-23744.
• [148]Amara A, Vidy A, Boulla G, Mollier K, Garcia-Perez J, Alcami J, Blanpain C, Parmentier M, Virelizier JL, Charneau P, Arenzana-Seisdedos F: G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. Journal of Virology 2003, 77:2550-2558.
• [149]Stolp B, Fackler OT: How HIV takes advantage of the cytoskeleton in entry and replication. Viruses 2011, 3:293-311.
• [150]Taylor MP, Koyuncu OO, Enquist LW: Subversion of the actin cytoskeleton during viral infection. Nat Rev Microbiol 2011, 9:427-439.
• [151]Lehmann M, Nikolic DS, Piguet V: How HIV-1 takes advantage of the cytoskeleton during replication and cell-to-cell transmission. Viruses 2011, 3:1757-1776.
• [152]Jolly C, Kashefi K, Hollinshead M, Sattentau QJ: HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004, 199:283-293.
• [153]Vasiliver-Shamis G, Cho MW, Hioe CE, Dustin ML: Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapse. J Virol 2009, 83:11341-11355.
• [154]Jolly C, Mitar I, Sattentau QJ: Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol 2007, 81:5547-5560.
• [155]Gladnikoff M, Shimoni E, Gov NS, Rousso I: Retroviral assembly and budding occur through an actin-driven mechanism. Biophys J 2009, 97:2419-2428.
• [156]Cooper J, Liu L, Woodruff EA, Taylor HE, Goodwin JS, D'Aquila RT, Spearman P, Hildreth JE, Dong X: Filamin A protein interacts with human immunodeficiency virus type 1 Gag protein and contributes to productive particle assembly. J Biol Chem 2011, 286:28498-28510.
• [157]Graziano F, Elia C, Laudanna C, Poli G, Alfano M: Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCepsilon. PLoS One 2011, 6:e23674.
• [158]Ansari AW, Bhatnagar N, Dittrich-Breiholz O, Kracht M, Schmidt RE, Heiken H: Host chemokine (C-C motif) ligand-2 (CCL2) is differentially regulated in HIV type 1 (HIV-1)-infected individuals. Int Immunol 2006, 18:1443-1451.
• [159]Damas JK, Landro L, Fevang B, Heggelund L, Froland SS, Aukrust P: Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy. Aids 2009, 23:135-138.
• [160]Damas JK, Landro L, Fevang B, Heggelund L, Tjonnfjord GE, Floisand Y, Halvorsen B, Froland SS, Aukrust P: Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication. Clin Exp Immunol 2009, 157:400-407.
• [161]Wu Y, Yoder A, Yu D, Wang W, Liu J, Barrett T, Wheeler D, Schlauch K: Cofilin activation in peripheral CD4 T cells of HIV-1 infected patients: a pilot study. Retrovirology 2008, 5:95. BioMed Central Full Text
• [162]Howard AD, McAllister G, Feighner SD, Liu Q, Nargund RP, Van der Ploeg LH, Patchett AA: Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol Sci 2001, 22:132-140.